Vertex’s ‘Slow Train To Pain’ R&D Rolls On
VX-548 Moves To Phase II
Executive Summary
Vertex is advancing its sodium channel inhibitor VX-548 to mid-stage trials in the second half of the year as a potential treatment for pain after bunionectomy and abdominoplasty procedures.
You may also be interested in...
Vertex Is The First To Get NaV1.8 To Proof Of Concept For Pain
Chief scientific officer David Altshuler talked to Scrip about the late-stage development plan for a drug that could represent a blockbuster-sized commercial opportunity, after two Phase II studies testing VX-548 met their primary endpoints.
Bluebird’s Latest Gene Therapy Stumble Will Help Vertex Close The Gap
Once the darling of biotech investors, Bluebird Bio’s go-it-alone strategy with Zynteglo has not paid off as German launch plans stall.
Merck Makes Its Debut In Pain With Pioneering New Analgesic Class
Merck & Co is moving into analgesia with a deal signed with Kings College London for an early program that has the potential to create a novel class of pain medications with reduced side effects.